Cancer therapy with decreased SARS-CoV-2 infection rates in cancer patients
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
The mammalian target of the rapamycin (mTOR) pathway has been demonstrated to be modulated by numerous RNA viruses. Recent evidence points toward modulation of mTOR in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Patients with cancer, who receive antineoplastic agents that suppress the mTOR/phosphoinositide 3-kinase (PI3K) signaling pathway, may have lower SARS-CoV-2 infection rates and coronavirus disease 2019 (COVID-19) severity.
COVID-19 pandemic urgently warranted the necessity to develop novel therapies against SARS-CoV-2 infection. The mammalian target of the rapamycin (mTOR) pathway has been demonstrated to be modulated in numerous RNA virus infections. Frequently. However, inhibiting mTOR results in the suppression of viral growth and replication. Recent scientific evidence points toward the modulation of mTOR in SARS-CoV-2 infection.
British Journal of Cancer , commentaire, 2021